Despite the enthusiasm surrounding novel targeted agents and immunotherapies,
chemotherapy remains the mainstay treatment for most human malignancies, either alone or …

Despite the importance of chemotherapy-associated adverse events in oncology practice
and the broad range of interventions available to mitigate them, limited systematic efforts …

The inception of cancer treatment with chemotherapeutics began in the 1940s with nitrogen
mustards that were initially employed as weapons in World War II. Since then, treatment …

A consistent system for reporting adverse events (AEs) is paramount in cancer clinical trials
and is crucial to ensure the safety and tolerability of chemotherapy. The shift towards …

Aims To assess incidence, predictability, preventability and severity of adverse drug
reactions (ADRs) in hospitalised oncology patients. Patients and methods Patients …

Correspondence to: Ethan Basch, MD, MSc, Department of Medicine, Health Outcomes
Research Group, and Center for Health Policy and Outcomes, Memorial Sloan-Kettering …

Purpose Adverse events in chemotherapy clinical trials are assessed and reported by
clinicians, yet clinician accuracy in assessing symptoms has been questioned. We …

Adverse event (AE)-related costs represent an important component of economic models for
cancer care. However, since previous studies mostly focused on specific AEs, treatments, or …

Purpose There is increasing interest to use patient-reported outcome (PRO) measures to
evaluate symptomatic adverse events (AEs) in cancer treatment trials. However, there are …

Importance Patient perspective on chemotherapy-related adverse effects is being
increasingly acknowledged both in experimental clinical trials and in clinical practice …